<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca H Allen, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Courtney A Schreiber, MD, MPH</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2653475844"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Combined estrogen-progestin oral contraceptives (COCs), also known as birth control pills, provide reliable contraception as well as several noncontraceptive benefits. COCs contain an estrogen component and one of a dozen different progestins  (<a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">table 1</a>). Low-dose COCs (formulations containing &lt;50 mcg ethinyl estradiol) are a safe and reliable contraceptive option for the vast majority of women [<a href="#rid1">1,2</a>]. For healthy, nonsmoking women, COCs may be continued until the age of menopause.</p><p>This topic will review the general principles of the use of COCs, including pharmacology, mechanisms of action, indications, contraindications, efficacy, and the different preparations that are available. Side effects and risks that may be associated with COCs, other forms of estrogen-progestin contraception, progestin-only oral contraceptives, and the selection of contraception in general are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5425.html" rel="external">"Contraception: Transdermal contraceptive patches"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16682.html" rel="external">"Contraception: Hormonal contraceptive vaginal rings"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5461.html" rel="external">"Contraception: Progestin-only pills (POPs)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a>.)</p><p></p><p>In this topic, when discussing study results, we will use the terms "women" or "patients" as they are used in the studies presented. We encourage the reader to consider the specific counseling and treatment needs of transgender and gender diverse individuals.</p><p class="headingAnchor" id="H3706272062"><span class="h1">OUR APPROACH TO COC SELECTION</span><span class="headingEndMark"> — </span>All COCs are effective and have similar advantages and disadvantages. Factors to take into consideration when selecting a COC include a patient's past experience with COCs, patient preferences, clinical characteristics, insurance coverage, relative safety considerations (side effects and relative risks may vary based on estrogen dose and progestin type and dose), and cost. Shared decision making that takes into account patient preferences will improve adherence to any contraceptive method [<a href="#rid3">3</a>]. Therefore, if a patient requests a particular pill, it is reasonable to prescribe it. Otherwise, we consider the following factors:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Generic versus brand name</strong> – In the United States, we prefer generic COCs due to affordability. Brand name COCs are more expensive out-of-pocket and have higher co-pays for women with health insurance coverage.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monophasic versus multiphasic</strong> – We prefer monophasic COCs as the initial prescription due to ease of use and consistent hormone dose, which improves adherence, a key component in COC effectiveness. Multiphasic COCs require more careful adherence to a specific sequential order in which to take the pills each cycle. Furthermore, multiphasic pills cannot be transitioned to continuous or extended-cycle use the way that monophasic pills can if the patient desires, although supporting data are limited [<a href="#rid4">4</a>]. There are also concerns that the changing hormone levels in multiphasic COCs could exacerbate mood symptoms in susceptible women (eg, those with premenstrual syndrome or premenstrual dysphoric disorder). (See  <a class="medical medical_review" href="/z/d/html/7382.html" rel="external">"Treatment of premenstrual syndrome and premenstrual dysphoric disorder", section on 'Combined estrogen-progestin contraception'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclic versus extended-cycle versus continuous use</strong> – Patients should be queried regarding achieving the frequency of withdrawal bleeding they desire. Some may prefer monthly withdrawal bleeding, while others may opt for every three months (84/7 formulations) or prefer no withdrawal bleeds (365 day formulations).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ethinyl estradiol dose</strong> – Women should be prescribed a COC with 35 mcg of ethinyl estradiol or less. The data regarding safety of 20 mcg versus 25, 30, or 35 mcg ethinyl estradiol COCs suggest less risk with 20 mcg formulas but are not strong enough to endorse higher safety with 20 mcg pills [<a href="#rid5">5-8</a>]. Nevertheless, it makes sense to start with a 20 mcg dose, and that can then be increased if unscheduled bleeding is a problem [<a href="#rid9">9</a>]. COCs containing 50 mcg of ethinyl estradiol should generally not be used for contraception but are available for the acute treatment of uterine bleeding. (See  <a class="medical medical_review" href="/z/d/html/5415.html" rel="external">"Managing an episode of acute uterine bleeding"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progestin type</strong> – Given that all COCs are antiandrogenic when the combined effects of both estrogen and progestin are considered, we do not preferentially prescribe based on particular progestin when considering hyperandrogenic symptoms. Part of the reason for this choice is that the data surrounding venous thromboembolism risk and progestin type are conflicting [<a href="#rid10">10</a>]. There may be a slightly increased risk with newer progestins (gestodene, desogestrel, and <a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">drospirenone</a>) compared with <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">levonorgestrel</a>; however, the absolute risk is extremely low for all COCs. Hence, the evidence is not compelling enough to change prescribing patterns [<a href="#rid7">7,11</a>]. This issue is reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Cardiovascular effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>21/7 versus 24/4</strong> – We prefer 24/4 to 21/7 formulations if feasible due to emerging evidence about increased efficacy associated with efforts to lower the estrogen content (especially for obese women) and decreased hormone withdrawal side effects during the hormone-free interval [<a href="#rid12">12</a>].</p><p></p><p class="headingAnchor" id="H4171659430"><span class="h1">MECHANISMS OF ACTION</span><span class="headingEndMark"> — </span>The main contraceptive efficacy of COCs is suppression of ovulation by inhibition of gonadotropin-releasing hormone (GnRH) from the hypothalamus, as well as inhibition of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and disruption of the mid-cycle LH surge. These effects are mediated by both the progestin and estrogen component of the COC working synergistically, but it is estrogen's ability to suppress FSH and thus prevent folliculogenesis that is likely the most important mechanism  (<a class="graphic graphic_table graphicRef120135" href="/z/d/graphic/120135.html" rel="external">table 2</a>). The additional estrogen exposure in pills with a shorter pill-free interval, pills with an additional 10 mcg ethinyl estradiol in the placebo week, or continuous-use pills results in a more complete suppression of FSH and less folliculogenesis. However, a substantial number of women can still develop follicles while taking a low-dose COC [<a href="#rid13">13,14</a>]. Additionally, the estrogen component stabilizes sufficient endometrium production to maintain a regular withdrawal bleeding pattern (cycle control).</p><p>Additional progestin-related mechanisms that contribute to the contraceptive effect include:</p><p class="bulletIndent1"><span class="glyph">●</span>Effects on the endometrium, rendering it less suitable for implantation. Long-term cyclic or daily progestin exposure leads to endometrial decidualization and eventual atrophy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thickening of cervical mucus, which becomes less permeable to penetration by sperm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Impairment of normal tubal motility and peristalsis.</p><p></p><p>The effects of progestins are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5461.html" rel="external">"Contraception: Progestin-only pills (POPs)", section on 'Mechanism and duration of action'</a>.)</p><p class="headingAnchor" id="H3637815015"><span class="h1">CANDIDATES</span></p><p class="headingAnchor" id="H550509944"><span class="h2">Eligibility</span><span class="headingEndMark"> — </span>Information to help guide a patient through the contraceptive options and method selection is presented separately. (See  <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a>.)</p><p>We and other experts use both the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) comprehensive tables of medical conditions and personal characteristics that may affect contraceptive choice [<a href="#rid15">15,16</a>]. While these advisory documents are generally similar, clinicians should select whichever best fit their population. Summary tables can be found through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=7398" target="_blank">CDC's Summary Chart of US Medical Eligibility Criteria</a> and the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F181468%2F9789241549158_eng.pdf&amp;token=n6AKfPMLO9no%2BCQ6AfHDii7sbay3dEwW4U5WgmUeAmSyIYzji9%2BF1lOqBBPOTPPcT4tVCzsD4vn9jlct6ayBxQSmDqBTeNp0ZZSS3AqYiKg%3D&amp;TOPIC_ID=7398" target="_blank">WHO Medical Eligibility Criteria for Contraceptive Use 2015</a>. COCs can be given from menarche until menopause in otherwise eligible women [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H3796391448"><span class="h2">Unacceptable risk</span><span class="headingEndMark"> — </span>Based upon the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=7398" target="_blank">CDC's Summary Chart of US Medical Eligibility Criteria</a> and the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F181468%2F9789241549158_eng.pdf&amp;token=n6AKfPMLO9no%2BCQ6AfHDii7sbay3dEwW4U5WgmUeAmSyIYzji9%2BF1lOqBBPOTPPcT4tVCzsD4vn9jlct6ayBxQSmDqBTeNp0ZZSS3AqYiKg%3D&amp;TOPIC_ID=7398" target="_blank">WHO Medical Eligibility Criteria for Contraceptive Use 2015</a> Category 4 rating, some common medical conditions that represent an "unacceptable health risk" for COC initiation include [<a href="#rid15">15,16</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Age ≥35 years and smoking ≥15 cigarettes per day</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple risk factors for arterial cardiovascular disease (such as older age, smoking, diabetes, and hypertension)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension (systolic ≥160 mmHg or diastolic ≥100 mmHg)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Venous thromboembolism (VTE; unless on anticoagulation) (see  <a class="medical medical_review" href="/z/d/html/5479.html" rel="external">"Contraception: Counseling for women with inherited thrombophilias", section on 'Personal history of venous thrombosis'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Known ischemic heart disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of stroke</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complicated valvular heart disease (pulmonary hypertension, risk for atrial fibrillation, history of subacute bacterial endocarditis)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Current breast cancer</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe (decompensated) cirrhosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatocellular adenoma or malignant hepatoma</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Migraine with aura</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes mellitus of &gt;20 years duration or with nephropathy, retinopathy, or neuropathy</p><p></p><p>The risk of VTE in individuals with known thrombogenic variants is elevated at baseline, a risk that is further increased with COC use. In general, estrogen-containing contraceptives should be avoided for these people. However, COCs may be used in carefully counseled patients, especially those with only mild thrombophilias (eg, heterozygous factor V Leiden or prothrombin variant) and no personal or family history of VTE, with a strong medical rationale for COC use. (See  <a class="medical medical_review" href="/z/d/html/5479.html" rel="external">"Contraception: Counseling for women with inherited thrombophilias", section on 'No personal or family history of VTE, but positive testing for inherited thrombophilia'</a>.)</p><p>The risks associated with COCs, particularly for the cardiovascular system, are presented in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns"</a>.)</p><p class="headingAnchor" id="H1049875574"><span class="h2">Risks outweigh benefits</span><span class="headingEndMark"> — </span>Based upon the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=7398" target="_blank">CDC's Summary Chart of US Medical Eligibility Criteria</a> and the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F181468%2F9789241549158_eng.pdf&amp;token=n6AKfPMLO9no%2BCQ6AfHDii7sbay3dEwW4U5WgmUeAmSyIYzji9%2BF1lOqBBPOTPPcT4tVCzsD4vn9jlct6ayBxQSmDqBTeNp0ZZSS3AqYiKg%3D&amp;TOPIC_ID=7398" target="_blank">WHO Medical Eligibility Criteria for Contraceptive Use 2015</a> Category 3 rating, there are also medical conditions for which the "theoretical or proven health risks usually outweigh the advantages" of using the method [<a href="#rid15">15,16</a>]. Nevertheless, the method still may be used if nothing else is available or acceptable to the patient and they have been counseled about the potential risks. Follow-up may be needed to ensure that continued use is safe.</p><p>Some of these conditions include [<a href="#rid15">15-17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Age ≥35 years and smoking &lt;15 cigarettes per day</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension (systolic 140 to 159 mmHg or diastolic 90 to 99 mmHg) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension adequately controlled on medications (See  <a class="medical medical_review" href="/z/d/html/3827.html" rel="external">"Contraception: Hormonal contraception and blood pressure"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Past breast cancer and no evidence of current disease for five years</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Current gallbladder disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malabsorptive bariatric surgery (see  <a class="medical medical_review" href="/z/d/html/5470.html" rel="external">"Contraception: Counseling for females with obesity", section on 'Contraception pre- and post-bariatric surgery'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Superficial venous thrombosis (acute or history)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inflammatory bowel disease with risk factors for VTE (active or extensive disease, surgery, immobilization, corticosteroid use, vitamin deficiencies, or fluid depletion)</p><p></p><p>The risks and side effects of COCs are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns"</a>.)</p><p class="headingAnchor" id="H553504697"><span class="h1">COUNSELING POINTS</span><span class="headingEndMark"> — </span>In addition to the discussions below for COCs, summaries of efficacy, advantages, and disadvantages of all contraceptive options can be found at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcontraceptivechoice.wustl.edu%2F&amp;token=rEOiMmP0WLFdqBXg2jh7TIorVxf%2BwV%2FRgbvXDqxld89HIJQEcdo2sSNbAnirQmRK&amp;TOPIC_ID=7398" target="_blank">The Contraceptive Choice Project</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.plannedparenthood.org%2F&amp;token=xXI%2By9QNEPjV52%2B%2BDeHAeZ9SXc2ukqt22nAmmnoIhbmjKCcbIKeiWKTXDj94bQ%2F4&amp;TOPIC_ID=7398" target="_blank">Planned Parenthood</a>, and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.bedsider.org%2F&amp;token=h7Ird6MEQJ0ciS3wlIS74wS%2BbqJQEspyaSo36FRNdkGJJnrJaPDlUEGuXmILPu5F&amp;TOPIC_ID=7398" target="_blank">BedSider.org</a>.</p><p class="headingAnchor" id="H2200657982"><span class="h2">Efficacy</span><span class="headingEndMark"> — </span>When taken properly, COCs are a highly effective form of contraception  (<a class="graphic graphic_figure graphicRef119765" href="/z/d/graphic/119765.html" rel="external">figure 1</a>). Although the perfect-use failure rate is 0.3 percent, the typical-use failure rate approximates 7 percent (ethinyl estradiol formulas), due primarily to missed pills, drug-drug interactions, or failure to resume therapy after the pill-free interval  (<a class="graphic graphic_table graphicRef120134" href="/z/d/graphic/120134.html" rel="external">table 3</a>) [<a href="#rid18">18</a>]. COCs are available in many formulations  (<a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">table 1</a>). There is no evidence that generic COCs are less effective than brand name COCs or that different COCs have different perfect-use failure rates, although few comparative studies have been performed [<a href="#rid19">19-21</a>]. The author typically prescribes generic formulations as they are lower cost. Other drug factors that impact efficacy include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Estrogen dose</strong> – Efficacy appears to be similar across a wide range of estrogen doses, which likely reflects the multiple effects of exogenous estrogen and the impact of the progestin component. (See <a class="local">'Mechanisms of action'</a> above.)</p><p></p><p class="bulletIndent1">In a meta-analysis of 13 trials, contraceptive efficacy appeared to be similar with COCs containing 20 mcg ethinyl estradiol when compared with pills with &gt;20 mcg of ethinyl estradiol [<a href="#rid5">5</a>]. An even lower dose estrogen preparation, containing only 10 mcg of ethinyl estradiol, is also available, which may have similar contraceptive efficacy but definitive conclusions are limited because of the high discontinuation rates reported in the studies [<a href="#rid22">22</a>]. However, the incidence of unscheduled bleeding may differ according to estrogen dose, as discussed below. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Estrogen type</strong> – The typical-use failure rate for COCs containing ethinyl estradiol approximates 7 percent  (<a class="graphic graphic_table graphicRef120134" href="/z/d/graphic/120134.html" rel="external">table 3</a>) [<a href="#rid18">18</a>]. Studies suggest that COCs containing estradiol valerate (with <a class="drug drug_general" data-topicid="17068" href="/z/d/drug information/17068.html" rel="external">dienogest</a>) and estetrol (with <a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">drospirenone</a>) are also highly effective [<a href="#rid23">23-26</a>]. One COC type is not clearly superior as long-term typical-use data are limited for estradiol valerate- and estetrol-containing formulations. </p><p></p><p class="bulletIndent1">For example, in a secondary analysis of pooled data from two multicenter trials evaluating estetrol with <a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">drospirenone</a>, the unintended pregnancy rate was 0.09 percent per cycle (which equates to 1.2 percent for 13 cycles, 31 on-treatment pregnancies in 26,455 at-risk cycles) for the entire group, ages 16 to 50 years [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progestin type</strong> – Efficacy appears to be similar across the multiple synthetic progestins used in COCs  (<a class="graphic graphic_table graphicRef120135" href="/z/d/graphic/120135.html" rel="external">table 2</a>), although comparative trial data are limited [<a href="#rid5">5,27-31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of hormone-free interval</strong> – Since the original oral contraceptive was first introduced in 1960, most birth control pill formulations have had 21 days of hormonally active pills followed by seven days of placebo pills (known as 21/7 regimens). Alternate formulations that either reduce the pill-free interval or introduce low doses of estrogen during the traditional placebo week (known as 24/4 regimens) have been created with the goal of reducing the duration of hormone-free time and resultant side effects (eg, withdrawal bleeding, menstrual migraines) [<a href="#rid12">12,32</a>]. With the shorter hormone-free interval of four days compared with seven days, ovarian follicular activity is better suppressed [<a href="#rid33">33-35</a>]. This enhanced follicular suppression has the potential to lead to increased efficacy, as reported in one study [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of obesity</strong> – While oral contraceptives are generally effective are preventing pregnancy in patients with obesity, they may be less forgiving of imperfect use. (See  <a class="medical medical_review" href="/z/d/html/5470.html" rel="external">"Contraception: Counseling for females with obesity", section on 'Efficacy'</a>.) </p><p></p><p class="headingAnchor" id="H2572069474"><span class="h2">Advantages</span><span class="headingEndMark"> — </span>In addition to high contraceptive efficacy, COCs have many advantages including rapid reversibility, regulation of menstrual bleeding, decreased menstrual blood loss, and dysmenorrhea, as well as population-level reductions in the risk of ovarian and endometrial cancers. Due to these effects and the ability of COCs to suppress ovulation, they have a number of noncontraceptive uses and benefits  (<a class="graphic graphic_table graphicRef82147" href="/z/d/graphic/82147.html" rel="external">table 4</a>).</p><p class="headingAnchor" id="H1553807477"><span class="h2">Noncontraceptive uses</span><span class="headingEndMark"> — </span>COCs are also used widely to treat a variety of gynecologic disorders including:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Menstrual cycle disorders</strong> – COCs are often used in women with menstrual cycle disorders, such as oligomenorrhea due to polycystic ovary syndrome, abnormal uterine bleeding (eg, midcycle spotting or heavy menstrual bleeding), menstrual migraines, and premenstrual syndrome or premenstrual dysphoric disorder (although COCs are not considered first-line therapy for this).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/7421.html" rel="external">"Treatment of polycystic ovary syndrome in adults", section on 'Menstrual dysfunction'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management", section on 'Estrogen-progestin contraceptives'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/5423.html" rel="external">"Hormonal contraception for menstrual suppression"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/5441.html" rel="external">"Estrogen-associated migraine headache, including menstrual migraine", section on 'Can estrogen-containing contraceptives reduce migraine headache frequency?'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/7382.html" rel="external">"Treatment of premenstrual syndrome and premenstrual dysphoric disorder"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/5478.html" rel="external">"Uterine fibroids (leiomyomas): Treatment overview", section on 'Medical therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pelvic pain disorders</strong> – Women with pelvic pain (eg, endometriosis-related or chronic pelvic pain) or dysmenorrhea often benefit from the hormonal and endometrial suppression associated with COC use to reduce their symptoms. Continuous or extended-cycle COCs are often more effective in this population compared with cyclic use.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain", section on 'Estrogen-progestin contraceptives'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/5435.html" rel="external">"Chronic pelvic pain in adult females: Treatment", section on 'Specific role of empiric hormonal therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/5414.html" rel="external">"Dysmenorrhea in adult females: Treatment", section on 'Hormonal contraception'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ovarian cysts</strong> – COCs are often prescribed to women with a history of painful ovarian cysts to suppress ovulation and subsequent formation of new cysts. COCs do not appear to aid regression of existing functional ovarian cysts [<a href="#rid37">37,38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperandrogenism</strong> – COCs can reduce the dermatologic manifestations of hyperandrogenism, such as acne and hirsutism, which are particularly common in women with polycystic ovary syndrome or nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. The relevant mechanisms of action for this population include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inhibition of gonadotropin secretion and thereby a decrease in ovarian androgen secretion.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An increase in serum sex hormone-binding globulin concentrations, which results in increased binding of androgens and a decrease in serum-free androgen concentrations.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inhibition of adrenal androgen secretion [<a href="#rid39">39</a>]; the mechanism of the last effect is not well understood.</p><p></p><p class="bulletIndent1">These issues are presented in greater detail in separate reviews:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">"Management of hirsutism in premenopausal women", section on 'Combined estrogen-progestin oral contraceptives'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/7421.html" rel="external">"Treatment of polycystic ovary syndrome in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/147.html" rel="external">"Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on 'Women'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other disorders</strong> – COCs can also be used as hormone replacement in women with primary hypogonadism or premature ovarian insufficiency. (See  <a class="medical medical_review" href="/z/d/html/7435.html" rel="external">"Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)"</a> and  <a class="medical medical_review" href="/z/d/html/7426.html" rel="external">"Management of primary ovarian insufficiency (premature ovarian failure)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cancer risk reduction</strong> – Women at increased risk of endometrial and ovarian cancer can benefit from COC use to reduce their cancer risk as well as to provide a highly effective contraceptive [<a href="#rid40">40</a>]. There is a similar reduction in risk for women with <em>BRCA1 </em>or <em>BRCA2</em> ovarian cancers [<a href="#rid41">41</a>]. Although a history of COC use has been associated with reduced risk of colorectal cancer in some studies, the body of evidence conflicts, and it is not known if prophylactic use of COCs reduces colorectal cancer risk.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/3249.html" rel="external">"Endometrial carcinoma: Epidemiology, risk factors, and prevention", section on 'Use of hormonal contraception'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/758.html" rel="external">"Cancer risks and management of BRCA1/2 carriers without cancer", section on 'Oral contraceptives'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone health</strong> – Perimenopausal women who use COCs have improved bone density compared with nonusers [<a href="#rid42">42</a>]. COCs are also useful for the treatment of hot flashes and abnormal uterine bleeding in this population [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/7395.html" rel="external">"Clinical manifestations and diagnosis of menopause", section on 'Long-term consequences of estrogen deficiency'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy", section on 'Use of oral contraceptives during the menopausal transition'</a>.)</p><p></p><p class="headingAnchor" id="H591898128"><span class="h2">Risks and side effects</span><span class="headingEndMark"> — </span>The risks and side effects of COCs are influenced by the type and dose of estrogen and the progestin. These issues are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns"</a>.)</p><p>Briefly, common issues that we discuss with patients initiating or using COCs include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Frequent patient concerns</strong> – We review that patients may experience breast tenderness, nausea, and bloating when starting a COC. These symptoms typically resolve quickly. Other concerns can include unscheduled bleeding, which typically resolves within three months, and the possible impact of COCs on mood and sexual function. There is no evidence that COCs cause weight gain. (See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Common side effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Venous thromboembolism (VTE)</strong> – COC use has been associated with an increased risk of VTE. The risk of VTE varies with estrogen dose and patient factors such as age, obesity, and smoking status. While the relative risk is increased, the absolute increase in risk is still low for most women and does not outweigh the numerous benefits of this contraceptive method, particularly when compared with the VTE risk during pregnancy and the postpartum period [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Cardiovascular effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular risk</strong> –<strong> </strong>COC use has been associated with increased risks of hypertension, myocardial infarction, and stroke in certain populations. However, the absolute risk of myocardial infarction and stroke attributable to COCs is low in women of reproductive age [<a href="#rid10">10</a>]. COCs can rarely cause a mild elevation in blood pressure in the range of 3 to 5 mmHg, which is unlikely to be clinically significant in healthy women. (See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Cardiovascular effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cancer risk</strong> – COC use does <strong>not</strong> appear to increase the overall risk of cancer [<a href="#rid40">40</a>]. The impact of COC use on breast cancer risk is a subject of active debate as the data conflict. At least one study has reported a differing risk of breast cancer with COC use based on hormone receptor subtype. Women who have taken COCs also appear to have a slightly increased risk for developing cervical cancer [<a href="#rid45">45</a>]. By contrast, COC use is associated with reduced risk of developing ovarian and endometrial cancers. These issues are presented in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Effects on cancer development'</a>.)</p><p></p><p class="headingAnchor" id="H687797132"><span class="h2">Impact on STI acquisition</span><span class="headingEndMark"> — </span>The impact of sexually transmitted infection (STI) acquisition in women using COCs appears to vary by type of infection. Two systematic reviews reported that COC use positively correlates with chlamydia infections but not with gonorrhea, herpes simplex virus-2, trichomoniasis, syphilis, and human papillomavirus [<a href="#rid46">46,47</a>]. While COCs may be associated with increased rates of chlamydia, the rates of pelvic inflammatory disease (PID) do not appear to be increased [<a href="#rid48">48</a>].</p><p>One study reported similarly increased rates of bacterial vaginosis, trichomoniasis, and <em>Candida</em> vaginitis among women initiating either COCs or a <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">levonorgestrel intrauterine device</a>, which makes sexual exposure the likely risk factor for these infections and not the type of contraceptive method [<a href="#rid49">49</a>]. Other studies have reported reduced rates of bacterial vaginosis in women using COCs [<a href="#rid50">50,51</a>]. Data generally do not support any influence of COC use on acquisition of HIV [<a href="#rid52">52-55</a>]. There are no restrictions on COC use among women with STIs, PID, or HIV [<a href="#rid15">15,56</a>].</p><p>We discuss STI risk with all women presenting for contraceptive counseling. Women at risk for acquiring an STI are advised to use condoms (male or female) in addition to their contraceptive method. (See  <a class="medical medical_review" href="/z/d/html/5471.html" rel="external">"Internal (formerly female) condoms", section on 'Sexually transmitted infections'</a> and  <a class="medical medical_review" href="/z/d/html/5463.html" rel="external">"External (formerly male) condoms", section on 'Protection from STIs'</a>.)</p><p class="headingAnchor" id="H2772577359"><span class="h1">HORMONE COMPONENTS</span></p><p class="headingAnchor" id="H527070505"><span class="h2">Estrogen</span><span class="headingEndMark"> — </span>The discovery in 1938 that the addition of a 17-alpha-ethinyl group to estradiol resulted in both an orally active estrogen compound and a dramatic increase in estrogenic potency was a major advance in steroid biochemistry. This compound, known as mestranol, was the estrogen used in the first COCs. Mestranol is metabolized to ethinyl estradiol in its first pass through the liver.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Estrogens used in COCs</strong> – Most, but not all, COCs contain ethinyl estradiol as the estrogen component  (<a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ethinyl estradiol</strong> – Ethinyl estradiol, the mostly commonly used estrogen in combined oral contraceptive pills, is a potent synthetic estrogen (like most analogs of naturally occurring hormone) with similar but not identical metabolic effects to estradiol regardless of the route of administration because of its long half-life and slow metabolism [<a href="#rid57">57</a>]. By contrast, some newer COC combinations utilize natural estradiol rather than ethinyl estradiol.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other estrogens</strong> – COCs containing estradiol valerate with the progestin dienogest, 17-beta estradiol with nomegestrol acetate, and estetrol with drospirenone have been released  (<a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">table 1</a>) [<a href="#rid23">23-26,58</a>]. Two milligrams of estradiol valerate is approximately equivalent to 10 mcg of ethinyl estradiol [<a href="#rid59">59</a>]. These estrogens appear to have less effect on hemostasis, fibrinolysis markers, lipids, and adrenal steroids compared with ethinyl estradiol [<a href="#rid25">25,60</a>]. Whether the estradiol valerate, 17-beta estradiol, or estetrol COCs will be safer than those formulated with ethinyl estradiol with respect to thromboembolism risk is unknown [<a href="#rid7">7,61</a>]. Additional information on COCs containing other estrogens is available in the <a class="drug drug_general" data-topicid="15573" href="/z/d/drug information/15573.html" rel="external">estradiol-dienogest</a> and <a class="drug drug_general" data-topicid="131362" href="/z/d/drug information/131362.html" rel="external">estetrol-drospirenone</a> drug information monographs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Estrogen doses</strong> – While early COC preparations contained up to 150 mcg of mestranol, available COCs contain, on average, 20 to 35 mcg of ethinyl estradiol. A few 50 mcg dose pills are still manufactured, and there is a 10 mcg pill available as well  (<a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. While universal consensus on the dose categories is lacking, we think of COCs based on the amount of ethinyl estradiol, or its equivalent, as below:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>High dose</strong> – In general, high-dose COCs contain ≥50 mcg ethinyl estradiol or its equivalent. Initial COCs contained 150 mcg of mestranol or ethinyl estradiol. However, common side effects such as nausea and vomiting, as well as high risk of venous thromboembolism, subsequently led to their discontinuation [<a href="#rid62">62</a>]. The next formulations contained 100 and then 50 mcg of ethinyl estradiol, which improved tolerability, but side effects and risks remained significant. In general, formulations with 50 mcg ethinyl estradiol pills are utilized for the acute treatment of abnormal uterine bleeding. (See  <a class="medical medical_review" href="/z/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Low dose</strong> – Contemporary low-dose COCs contain 20 to 35 mcg of ethinyl estradiol. COCs with 20 to 25 mcg ethinyl estradiol were introduced as options for individuals who did not tolerate the 30 or 35 mcg products, as well as for business-related reasons such as patent expiration and competition for market advantage. Compared with 30 to 35 mcg ethinyl estradiol COCs, COCs containing 20 mcg are more likely to result in bleeding disturbances, including amenorrhea and irregular, frequent bleeding, or spotting [<a href="#rid5">5</a>]. However, many of the clinical trials comparing different doses of estrogen used COCs that also contained different types of progestins. As a result, it is unclear whether the higher frequency of bleeding was due to the lower estrogen dose or to different progestin types.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ultra-low dose</strong> – COCs with less than 20 mcg ethinyl estradiol are available in multiphasic combination COC products  (<a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">table 1</a>). While dose reductions from 150 mcg ethinyl estradiol to 30 to 35 mcg resulted in a markedly improved safety profile for COCs, it is unknown if subsequent dose reductions to 20 or 10 mcg will further decrease adverse events [<a href="#rid5">5,6</a>]. For comparison, the contraceptive vaginal rings release 13 to 15 mcg ethinyl estradiol per day. (See  <a class="medical medical_review" href="/z/d/html/16682.html" rel="external">"Contraception: Hormonal contraceptive vaginal rings"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased risk of thromboembolism</strong> – In general, the increased risk of venous thromboembolism is related to estrogen's stimulation of liver proteins involved in the clotting system. The progestin component may modulate this effect significantly, and more antiandrogenic progestins are thought to allow a fuller expression of the estrogen component [<a href="#rid10">10</a>]. Due to this feature, concerns have been raised about possible increased risk of deep venous thrombosis with the third-generation progestins (gestodene and desogestrel, but <strong>not</strong> norgestimate) and antiandrogenic progestins (<a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">drospirenone</a> and <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">cyproterone acetate</a>) when compared with COCs containing <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">levonorgestrel</a>  (<a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">table 1</a>) [<a href="#rid6">6,44</a>]. This issue is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Cardiovascular effects'</a> and <a class="local">'Progestin'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact on other hormones</strong> – The estrogen component of COC pills, like any estrogen taken orally, raises the serum concentrations of thyroxine-binding globulin (TBG), cortisol-binding globulin (CBG), and sex hormone-binding globulin (SHBG). As a result, the serum concentrations of total thyroxine (T4), triiodothyronine (T3), cortisol, estradiol, and testosterone increase, but the serum concentrations of free T4, T3, cortisol, estradiol, and testosterone do not change. This effect of oral estrogen administration needs to be considered when evaluating tests of thyroid, adrenal, and gonadal function in women taking any estrogen orally.</p><p></p><p class="headingAnchor" id="H64774081"><span class="h2">Progestin</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progestins </strong>– The designation of first-, second-, third-, and fourth-generation progestin refers to when the group of progestins was introduced into the market, not on structural and physiologic differences  (<a class="graphic graphic_table graphicRef87416" href="/z/d/graphic/87416.html" rel="external">table 5</a>). In general, third- and fourth-generation progestins are less androgenic and have fewer side effects than earlier generation progestins. Modifications to <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">levonorgestrel</a> created the third-generation progestins desogestrel, gestodene, and norgestimate [<a href="#rid63">63,64</a>]. However, some of these later generation progestins (gestodene and desogestrel, but not norgestimate) have also been associated with a slightly greater risk of venous thromboembolism [<a href="#rid6">6,64</a>]. (See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Venous thromboembolism'</a>.)</p><p></p><p class="bulletIndent1">Progestins can also be divided based upon their structural derivation into estranes and gonanes (derived from testosterone) and pregnanes (derived from progesterone)  (<a class="graphic graphic_table graphicRef120135" href="/z/d/graphic/120135.html" rel="external">table 2</a>). The majority of progestins used in COCs are derived from testosterone and are, therefore, in the estrane and gonane classes. Individual progestins vary in their progestin potency, androgenicity, and side effects.  (<a class="graphic graphic_table graphicRef78782" href="/z/d/graphic/78782.html" rel="external">table 6</a>). <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">Norethindrone</a> and norethindrone acetate are in the class of progestins referred to as the estranes  (<a class="graphic graphic_table graphicRef120135" href="/z/d/graphic/120135.html" rel="external">table 2</a>). Ethynodiol diacetate, another progestin in this category, has more estrogenic activity than other progestins in this class. A second class of progestins known as gonanes (or 13-ethylgonanes) are also derived from testosterone and include <a class="drug drug_general" data-topicid="141983" href="/z/d/drug information/141983.html" rel="external">norgestrel</a> and <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">levonorgestrel</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiandrogenic progestins</strong> – Sometimes referred to as fourth-generation progestins, newer preparations have been developed that have some antiandrogenic activity  (<a class="graphic graphic_table graphicRef78782" href="/z/d/graphic/78782.html" rel="external">table 6</a>). These include a compound derived from <a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">drospirenone</a> (a <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> analog), <a class="drug drug_general" data-topicid="17068" href="/z/d/drug information/17068.html" rel="external">dienogest</a>, and <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">cyproterone acetate</a>, which is available worldwide but not in the United States  (<a class="graphic graphic_table graphicRef120135" href="/z/d/graphic/120135.html" rel="external">table 2</a>) [<a href="#rid63">63,64</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">Drospirenone</a> is structurally related to <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>; it has progestogenic, antiandrogenic, and anti-mineralocorticoid activity [<a href="#rid65">65</a>]. Monophasic COCs containing either 20 or 30 mcg of ethinyl estradiol with 3 mg of drospirenone are available [<a href="#rid66">66</a>]. Drospirenone appears to be a very weak antiandrogen; the 3 mg dose is estimated to be equivalent to only 25 mg of spironolactone. The 20 mcg preparation has a four-day pill-free interval, as opposed to the standard seven-day interval, and it is approved for the treatment of premenstrual dysphoric disorder (but not for premenstrual syndrome [eg, women with milder symptoms]) [<a href="#rid67">67,68</a>]. Although drospirenone is technically an antiandrogen, drospirenone-containing COCs have no advantage over other COCs for treating hirsutism or acne [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1">(See  <a class="medical medical_review" href="/z/d/html/7382.html" rel="external">"Treatment of premenstrual syndrome and premenstrual dysphoric disorder", section on 'Combined estrogen-progestin contraception'</a>.)</p><p></p><p class="bulletIndent1">(See  <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">"Management of hirsutism in premenopausal women", section on 'Choice of pill'</a>.)</p><p></p><p class="bulletIndent1">Although <a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">drospirenone</a> has potential potassium-sparing effects (due to its anti-mineralocorticoid activity), healthy women taking COCs containing drospirenone are no more likely to develop hyperkalemia than women taking other COC preparations [<a href="#rid70">70-72</a>]. Package labeling recommends potassium monitoring in the first month for women who take additional medications that predispose to hyperkalemia (eg, <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>, nonsteroidal anti-inflammatory drugs [NSAIDs], angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, and aldosterone antagonists) [<a href="#rid73">73</a>]. However, in one study, short-term coadministration of an <a class="drug drug_general" data-topicid="9310" href="/z/d/drug information/9310.html" rel="external">ethinyl estradiol-drospirenone</a> COC with <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">indomethacin</a> was associated with the same mean serum potassium and same low rate of serum potassium values above 5 mEq/L as indomethacin alone [<a href="#rid71">71</a>]. In clinical practice, we do not check potassium levels on women taking NSAIDs with drospirenone-containing COCs. However, we would consider potassium monitoring for the rare patient taking a drospirenone-containing COC along with the anti-hypertensives and diuretics listed above. Package labeling also advises against prescribing drospirenone to women with renal disease or adrenal insufficiency [<a href="#rid74">74</a>].</p><p></p><p class="headingAnchor" id="H3087783510"><span class="h2">Androgenicity</span><span class="headingEndMark"> — </span>Whether the differing androgenic activity of the available progestins in COCs has any meaningful clinical effects has been a matter of debate  (<a class="graphic graphic_table graphicRef78782" href="/z/d/graphic/78782.html" rel="external">table 6</a>). Any effect of the progestin will depend on the type, dose, potency, and estrogen/progestin balance in the COC formulation [<a href="#rid75">75,76</a>]. Estrogen is known to decrease low-density lipoprotein (LDL) and increase high-density lipoprotein (HDL), triglycerides, cholesterol, and SHBG. A progestin, depending on its level of androgenicity, may be neutral or may partially reverse some of these effects when the two hormones are taken together. The overall effect of all COCs, however, is antiandrogenic, regardless of the type of progestin used. There is no evidence that a certain type of progestin in a COC formulation is any more effective in treating hyperandrogenic symptoms, such as acne or hirsutism, for example, than another type [<a href="#rid69">69,77,78</a>], nor are any changes in lipid profiles typically clinically meaningful for the average woman [<a href="#rid79">79</a>].</p><p class="headingAnchor" id="H165837291"><span class="h1">DOSING REGIMENS</span></p><p class="headingAnchor" id="H2618551419"><span class="h2">Mono- or multiphasic</span><span class="headingEndMark"> — </span>COCs are available as mono- or multiphasic formulations  (<a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">table 1</a>). Monophasic pills contain the same dose of estrogen and progestin in each of the 21 to 24 hormonally active pills.</p><p>Multiphasic pills vary the dose of either or both hormones during the active pill phase. Multiphasic COCs were introduced as a strategy to reduce hormone dose and, thus, hormone-related side effects and unscheduled bleeding, as well as for business-related reasons such as patent expiration and competition for market advantage. However, there are no data that these preparations have any important clinical advantages; the contraceptive efficacy appears to be similar across all COC types. Biphasic formulations may be associated with more unscheduled bleeding compared with triphasic pills and therefore are not used [<a href="#rid27">27,29,31</a>].</p><p class="headingAnchor" id="H2506080921"><span class="h2">Cyclic use</span><span class="headingEndMark"> — </span>Cyclic pill packs typically provide hormone pills for 21 days of a 28-day cycle (monophasic, biphasic, or triphasic dosing regimens), followed by 7 days of placebo pills that result in a withdrawal bleed (also known as a 21/7 regimen). The original intent of the regimen was to provide a monthly bleed that patients would interpret as menstruation. This was required at the time for pill acceptance and to reassure the woman that she was not pregnant [<a href="#rid12">12</a>]. Today, with the lower doses of hormones used in COCs, it is recognized that seven days off hormones is not necessary. An alternative is the 24/4 regimen which provides four days of placebo or low-dose estrogen pills. The shorter the pill-free window, the less likely it is that folliculogenesis will occur [<a href="#rid33">33-35,80</a>]. With a standard seven-day pill-free interval, follicles may develop and secrete enough estradiol to "repair" or stimulate proliferation of the thin endometrium that is a normal consequence of the progestin in the pill [<a href="#rid35">35</a>]. With a four-day pill-free interval, on the other hand, endometrial atrophy may become more likely (which can result in more unscheduled bleeding in early cycles). Then again, the four-day hormone-free interval may be associated with increased efficacy [<a href="#rid36">36</a>]. Furthermore, shortening the hormone-free interval may reduce symptoms associated with hormone withdrawal (eg, mood symptoms, headache, pelvic pain) [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/z/d/html/5423.html" rel="external">"Hormonal contraception for menstrual suppression"</a>.)</p><p class="headingAnchor" id="H3380956948"><span class="h2">Continuous or extended use</span><span class="headingEndMark"> — </span>Continuous or extended-cycle COC regimens allow the user to choose if and when she will have withdrawal bleeding. Today, we know that menstrual suppression is safe, and the withdrawal bleed provided by the hormone-free interval is not medically necessary. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Continuous</strong> – With continuous regimens, the patient takes a combined estrogen-progestin pill every day for a year. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extended</strong> – Extended-cycle preparations are similar to continuous regimens, except that seven-day intervals of placebo or low-dose estrogen administration are inserted approximately every three months (84/7 regimen). These formulations are packaged so that the three-month supply is dispensed at one time in a convenient package. Sunday start is advised for new users of extended regimens. </p><p></p><p>Contraceptive efficacy, safety, and patient satisfaction are similar for cyclic, extended, and continuous regimens, while menses-related symptoms are typically reduced with combinations that reduce the frequency of withdrawal bleeding [<a href="#rid9">9</a>]. However, women using extended or continuous COCs may have more unpredictable bleeding or spotting events, which is due to the development of a thin, atrophic endometrium with continuous progestin exposure. Unscheduled bleeding is a common problem with continuous regimens in early cycles (the first three to six months) [<a href="#rid81">81,82</a>], but the frequency decreases over time and becomes similar to that for cyclic regimens [<a href="#rid9">9,83,84</a>]. Unscheduled bleeding is not a sign of decreased contraceptive efficacy, nor is it associated with an increased risk of endometrial hyperplasia [<a href="#rid85">85</a>]. Women should be counseled about potential changes in bleeding patterns prior to initiating these regimens. If the patient desires treatment for persistent unscheduled bleeding with continuous or extended-cycle COC regimens, they can opt to discontinue use for three to four consecutive days (except during the first 21 days of using the method) to give themselves a hormone-free interval [<a href="#rid86">86,87</a>]. This will ideally allow for a coordinated withdrawal bleed and reduce further unscheduled bleeding.</p><p>The reduction or elimination of withdrawal bleeding has been found helpful for the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endometriosis</strong> – The strategy with this approach is to induce decidualization and subsequent atrophy of endometrial tissue. This regimen may be as effective as a gonadotropin-releasing hormone agonist for pain control. (See  <a class="medical medical_review" href="/z/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain"</a> and  <a class="medical medical_review" href="/z/d/html/5423.html" rel="external">"Hormonal contraception for menstrual suppression"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Premenstrual dysphoric disorder (PMDD)</strong> – To reduce symptoms of PMDD by avoiding hormonal fluctuations. (See  <a class="medical medical_review" href="/z/d/html/7382.html" rel="external">"Treatment of premenstrual syndrome and premenstrual dysphoric disorder", section on 'Combined estrogen-progestin contraception'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperandrogenism </strong>– (See <a class="local">'Noncontraceptive uses'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lifestyle needs</strong> – For lifestyle reasons, many women without any underlying disease or disorder prefer to take the pill continuously to minimize the frequency of menses or avoid having their period during a specific event, such as a sports competition or vacation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of menopausal symptoms in perimenopausal women</strong> – Hot flashes recur if COCs are given in a cyclic regimen but will remain suppressed with a continuous regimen. (See  <a class="medical medical_review" href="/z/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy", section on 'Use of oral contraceptives during the menopausal transition'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dysmenorrhea</strong> – (See  <a class="medical medical_review" href="/z/d/html/5414.html" rel="external">"Dysmenorrhea in adult females: Treatment"</a>.)</p><p></p><p class="headingAnchor" id="H2963904499"><span class="h1">ADMINISTRATION AND USE</span><span class="headingEndMark"> — </span>COCs are available over the counter in the majority of countries worldwide but by prescription only in 30 percent of countries, including the United States [<a href="#rid88">88</a>].</p><p class="headingAnchor" id="H1603686843"><span class="h2">Screening requirements</span><span class="headingEndMark"> — </span>Hormonal contraception can be safely provided after a medical history and blood pressure measurement; a pelvic examination is not required [<a href="#rid87">87</a>]. Important factors to screen for in the patient's medical history include concurrent medications, smoking, hypertension, diabetes, venous and arterial thromboembolism, migraine with aura, breast cancer, and postpartum status. While known thrombogenic mutations are a contraindication to COCs, it is not recommended that testing be performed in the general population prior to initiating COCs [<a href="#rid17">17,87,89</a>]. Although breast examinations, Pap smears, and screening for sexually transmitted diseases are important, most groups, including the Centers for Disease Control and Prevention, the World Health Organization, and the Royal College of Obstetricians and Gynaecologists, agree that these procedures are not necessary before a first prescription for COCs [<a href="#rid11">11,15,16</a>]. Documentation of body mass index (BMI) prior to starting COCs is suggested because obese women are at greater risk for venous thromboembolism (VTE) with COC use and weight changes can be monitored. (See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Cardiovascular effects'</a> and  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Weight gain'</a>.)</p><p>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fvolumes%2F65%2Frr%2Frr6504a1.htm%3Fs_cid%3Drr6504a1_w&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLDUG08ZbGAJiu0qbyu%2F2zoI9S6tDFFGkqrofEu6x4BLSnjAf2YtkLNeW%2BABX%2FWfw0wprhImEEGXBTJh4uBFC8ZY%3D&amp;TOPIC_ID=7398" target="_blank">2016 United States Selected Practice Recommendations for Contraceptive Use</a> provide an overview of factors to consider when initiating contraception in healthy women, such as how to help a woman initiate use of a contraceptive method, which examinations and tests are needed before initiating use, what regular follow-up is needed, and how to address problems that often arise during use  (<a class="graphic graphic_table graphicRef89825" href="/z/d/graphic/89825.html" rel="external">table 7</a>) [<a href="#rid87">87</a>].</p><p class="headingAnchor" id="H3581460397"><span class="h2">Initiation</span><span class="headingEndMark"> — </span>COCs can be started any time during the cycle  (<a class="graphic graphic_algorithm graphicRef56863" href="/z/d/graphic/56863.html" rel="external">algorithm 1</a>) as long as pregnancy is reasonably excluded  (<a class="graphic graphic_table graphicRef67567" href="/z/d/graphic/67567.html" rel="external">table 8</a>) [<a href="#rid87">87</a>]. There are several options for starting the pill.</p><p class="bulletIndent1"><span class="glyph">●</span>We use the <strong>quick start</strong> method in which the woman begins taking COCs on the day that she is given the prescription [<a href="#rid90">90,91</a>]. This approach is evidence-based.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An alternative is the <strong>Sunday start</strong> approach where the woman starts the pill on the first Sunday after her period begins. The patient should be informed that a Sunday start avoids withdrawal bleeding on a weekend, and she can decide if that is a priority. Sunday start is advised for patients taking extended-cycle regimens. (See <a class="local">'Continuous or extended use'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Back-up contraception</strong> – If the patient will start taking the pill &gt;5 days after the onset of menses, then back-up (ie, nonhormonal) contraception is advised.  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration</strong> – Most patients are advised to use an additional, nonhormonal, contraceptive for the first seven days of the cycle [<a href="#rid87">87</a>]. Patients taking dienogest-containing pills are advised to use back-up contraception for a total of nine days [<a href="#rid92">92</a>]. Examples of nonhormonal contraception include condoms and pericoital methods.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/z/d/html/5471.html" rel="external">"Internal (formerly female) condoms"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/z/d/html/5463.html" rel="external">"External (formerly male) condoms"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See  <a class="medical medical_review" href="/z/d/html/3265.html" rel="external">"Pericoital (on demand) contraception: Diaphragm, cervical cap, spermicides, and sponge"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rationale</strong> – Back-up contraception is advised because follicular development and breakthrough ovulation are more common in patients who delay starting the pill after menses when compared with patients who start on day 1 of menses [<a href="#rid93">93</a>]. If the patient is concerned about the possibility of pregnancy, she should be instructed to check a pregnancy test at home or in the office two weeks after initiating COCs. Patients can be reassured that any exposure to COCs will not adversely affect an early pregnancy or cause congenital anomalies.</p><p></p><p>COCs can also be started in the following settings:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>First day of menses</strong> (known as the <strong>first day start</strong>) – The advantage of this approach is that it provides the maximum contraceptive effect in the first cycle, and backup contraception for the first seven days of use is not needed as it is with the first two options.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy loss or abortion</strong> – COCs can also be started within the first seven days following first- or second-trimester spontaneous or induced abortion. Backup contraception is needed for seven days unless COCs are started immediately after the abortion [<a href="#rid87">87</a>]. (See  <a class="medical medical_review" href="/z/d/html/109209.html" rel="external">"Contraception: Postabortion"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postpartum</strong> – Postpartum women should not use combined hormonal contraceptives for at least the first 21 days after delivery because of the increased risk for VTE during this time period [<a href="#rid15">15,94</a>]. Breastfeeding women should avoid combined hormonal contraceptives until 30 days postpartum due to theoretical effects on lactation. Postpartum women with other risk factors for VTE (eg, age 35 years or more, previous VTE, thrombophilia, immobility, transfusion at delivery, peripartum cardiomyopathy, BMI 30 kg/m<sup>2</sup>, postpartum hemorrhage, postcesarean delivery, preeclampsia, or smoking) generally should not use combined hormonal contraceptives until six weeks after delivery whether breastfeeding or not. This topic is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6708.html" rel="external">"Contraception: Postpartum counseling and methods", section on 'Counseling regarding venous thromboembolism risk and hormonal contraception in the postpartum period'</a>.)</p><p></p><p>COCs are prescribed as a monthly or an extended-cycle regimen, and a one-year supply is provided [<a href="#rid87">87</a>]. Providing a one-year prescription or, even better, a supply for a full year of pills has been shown to improve access to and continuation rates of the pill as well as anticipated cost savings [<a href="#rid95">95,96</a>].</p><p class="headingAnchor" id="H3055103726"><span class="h2">Follow-up</span><span class="headingEndMark"> — </span>Contraceptive follow-up can be addressed during routine periodic examinations scheduled for other health maintenance issues [<a href="#rid87">87</a>]. A specific follow-up examination just to address contraception is not needed for most women; potential exceptions include adolescents or women with multiple medical issues. Women should be encouraged to return if they have any concerns about their method or want to discontinue or switch methods.</p><p class="headingAnchor" id="H3239736488"><span class="h2">Missed pills</span><span class="headingEndMark"> — </span>Missed pills (particularly if the seven-day hormone-free interval is extended on either end) are a common cause of contraceptive failure. Our approach outlined here is similar to that suggested by the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fvolumes%2F65%2Frr%2Frr6504a1.htm%3Fs_cid%3Drr6504a1_w&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLDUG08ZbGAJiu0qbyu%2F2zoI9S6tDFFGkqrofEu6x4BLSnjAf2YtkLNeW%2BABX%2FWfw0wprhImEEGXBTJh4uBFC8ZY%3D&amp;TOPIC_ID=7398" target="_blank">2016 United States Selected Practice Recommendations for Contraceptive Use</a> [<a href="#rid87">87</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Missing a single pill</strong> – If a single pill is missed anywhere in the packet, women should be instructed to take the missed pill as soon as it is noticed and then continue taking one pill each day as prescribed [<a href="#rid87">87</a>]. Depending on when she remembers her missed pill, she may end up taking two pills on the same day. No additional contraception is required because one missed pill does not reverse ovarian suppression [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Missing two or more pills</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The remaining pills should be taken at the usual time, <strong>and</strong> backup contraception, such as male or female condoms, is generally needed if two or more consecutive hormonal pills are missed [<a href="#rid11">11,87</a>]. The risk of ovulation is thought to be increased following two or more missed pills, particularly in the first week of pill taking after the hormone-free interval, based on studies reporting less ovarian activity with continuous pill regimens compared with regimens that include a hormone-free interval [<a href="#rid84">84,97-99</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If two or more pills are missed in the <strong>first week</strong> of the cycle and unprotected intercourse occurs during this week, use of emergency contraception (with the exception of <a class="drug drug_general" data-topicid="15626" href="/z/d/drug information/15626.html" rel="external">ulipristal</a> acetate) could decrease the risk of pregnancy. Use of progestin-containing contraceptives at the same time as ulipristal acetate could lower the efficacy. (See  <a class="medical medical_review" href="/z/d/html/5475.html" rel="external">"Emergency contraception"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If pills were missed in the <strong>last </strong>week of hormone pills (week 3, days 15 to 21 of a 28-day pack), the patient should finish that last week of hormone pills (week 3), then skip week 4 (placebo pills), and immediately move on to a new pill pack the next day. If she is unable to start a new pack, backup contraception should be used until hormonal pills from a new pack are taken for seven consecutive days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extra pills</strong> – If the patient takes two pills in one day by mistake, she should resume her normal schedule of taking one pill daily the next day; she should not skip a day. She will complete the pill pack one day early.</p><p></p><p class="headingAnchor" id="H2706278194"><span class="h2">Return of menses after stopping</span><span class="headingEndMark"> — </span>For many women, menses returns within 30 days after stopping the pill. Almost all women should experience return of menses and fertility by 90 days after cessation of COCs. This is true for standard 28-day regimens, as well as the extended and continuous regimens  (<a class="graphic graphic_figure graphicRef117688" href="/z/d/graphic/117688.html" rel="external">figure 2</a>). Therefore, women who do not menstruate three months after stopping the pill should undergo the same evaluation for amenorrhea as any woman with amenorrhea. (See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Return of fertility'</a>.)</p><p class="headingAnchor" id="H3980015039"><span class="h2">Duration of use</span><span class="headingEndMark"> — </span>Hormonal contraception can be continued until the age of menopause (average age 50 to 51 years) in healthy, nonsmoking, normal-weight women [<a href="#rid15">15,43,87</a>]. There is no need for periodic pill-free intervals. Women can use COCs for years and stop only for pregnancy and/or menopause.</p><p class="headingAnchor" id="H1196585135"><span class="h3">Fertility in perimenopause</span><span class="headingEndMark"> — </span>While the risk of pregnancy declines during perimenopause, ovulatory cycles are still present in about 23 percent of cycles within one year of the final menstrual period [<a href="#rid100">100</a>]. The median age at which women lose their natural fertility is 41 years but can range up to 51 years [<a href="#rid101">101</a>].</p><p class="headingAnchor" id="H3078774093"><span class="h3">Age-based cessation of contraceptives</span><span class="headingEndMark"> — </span>Major medical organizations recommend that females at risk for pregnancy continue to use contraception until menopause or up to age 50 to 55 years [<a href="#rid87">87,102</a>]. The rationales for age-based management is that menopause is a retrospective diagnosis (after the cessation of menses for 12 months) and hormonal contraceptives will mask menstrual change. While the average age of menopause is 52 years in the United States, it can vary from ages 40 to 60 years [<a href="#rid102">102,103</a>].</p><p>The decision to stop using contraception as women approach their older reproductive years should consider their age, frequency of sexual intercourse, and male partner fertility, as well as the risks of carrying a pregnancy given their age and any other medical problems the patient may have. Single measurements of follicle-stimulating hormone (FSH) and estradiol levels in the perimenopausal period can be unreliable indicators of menopause given the dramatic hormonal fluctuations during this time. Furthermore, for individuals taking combined oral contraceptives, amenorrhea and laboratory measurements will not be a reliable indicator of menopause. (See  <a class="medical medical_review" href="/z/d/html/7395.html" rel="external">"Clinical manifestations and diagnosis of menopause", section on 'Women taking oral contraceptives'</a>.)</p><p class="headingAnchor" id="H1023679911"><span class="h1">DRUG INTERACTIONS</span><span class="headingEndMark"> — </span>The metabolism of COCs is accelerated by any drug that increases liver microsomal enzyme activity such as <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">griseofulvin</a>, and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>. As a result, the contraceptive efficacy of a COC is likely to be decreased in women taking these drugs [<a href="#rid15">15,104-107</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiseizure medications</strong> – We take the same approach as the Centers for Disease Control and Prevention and suggest that women taking antiseizure medications including <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, barbiturates, <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a>, <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>, <a class="drug drug_general" data-topicid="8934" href="/z/d/drug information/8934.html" rel="external">felbamate</a>, or <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a> should generally not use COCs because the antiseizure medication may reduce the efficacy of the hormonal contraceptive [<a href="#rid15">15</a>]. However, COCs are reasonable if the patient understands the risks and cannot use other methods. When a COC is chosen, a formulation containing a minimum of 30 mcg of ethinyl estradiol should be used, and consideration should be given to using progestins with a longer half-life (<a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">drospirenone</a>, desogestrel, <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">levonorgestrel</a>) and a continuous regimen or a preparation with a four-day hormone-free interval. (See  <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults", section on 'Contraception'</a>.)</p><p></p><p class="bulletIndent1">Antiseizure medications that do not appear to reduce contraceptive efficacy include <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">zonisamide</a>, and <a class="drug drug_general" data-topicid="10144" href="/z/d/drug information/10144.html" rel="external">tiagabine</a> [<a href="#rid15">15</a>]. By contrast, COCs increase <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> clearance, resulting in a decrease in plasma lamotrigine concentrations by 45 to 60 percent [<a href="#rid108">108,109</a>]. This interaction raises concerns about adequate seizure control if a COC and lamotrigine are used in combination, and the lamotrigine dose may need to be adjusted [<a href="#rid108">108,110,111</a>]. To avoid fluctuating levels of lamotrigine, we recommend using continuous dosing of the COC rather than cyclic. (See  <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults", section on 'Contraception'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotics</strong> – <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">Rifampin</a> is the only antibiotic proven to decrease serum ethinyl estradiol and progestin levels in women taking COCs [<a href="#rid106">106</a>]; similar to liver enzyme-inducing antiseizure medications, other methods of contraception are recommended [<a href="#rid15">15</a>]. </p><p></p><p class="bulletIndent1">For women taking antibiotics other than <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> with COCs, backup contraception is not required. In spite of anecdotal reports of COC failure, other antibiotics have <strong>not</strong> been proven to affect the pharmacokinetics of ethinyl estradiol [<a href="#rid111">111</a>]. While a database review reported a sevenfold increased rate of unintended pregnancy for patients taking non-enzyme-inducing antibiotics compared with control medications, this study was based on self-report and therefore subject to recall bias [<a href="#rid112">112</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antifungals</strong> – <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">Griseofulvin</a>, an antifungal agent, has been associated with contraceptive failure in several case reports [<a href="#rid105">105</a>]. However, data are limited, and the World Health Organization concludes that hormonal contraception is reasonable for women on griseofulvin [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiretrovirals</strong> – Drug interactions between COCs and many of the drugs used to treat HIV infection are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3753.html" rel="external">"HIV and women", section on 'Choice of contraception'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>St. John's wort</strong> – Limited evidence suggests that St. John's wort coadministration with COCs may increase the risk of ovulation and unscheduled bleeding [<a href="#rid113">113</a>]. The mechanism is thought to be via induction of cytochrome P450, which could increase COC metabolism and theoretically reduce therapeutic efficacy. The effect would depend on the dose of St. John's wort, which varies across products.</p><p></p><p class="headingAnchor" id="H3045622229"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H491371217"><span class="h2">Adolescents</span><span class="headingEndMark"> — </span>COCs may be challenging for adolescents to use successfully due to the daily adherence required and the need to refill a prescription each month. They will benefit from support surrounding COC adherence. (See  <a class="medical medical_review" href="/z/d/html/107.html" rel="external">"Contraception: Issues specific to adolescents"</a>.)</p><p class="headingAnchor" id="H1514338188"><span class="h2">Obesity</span><span class="headingEndMark"> — </span>Obese women who are not perimenopausal can use COCs, as the benefits are generally believed to outweigh the risks [<a href="#rid15">15,17</a>]. COCs should be used with caution in obese perimenopausal women, as the risk of venous thromboembolism increases with both age and body mass index; risk appears to be twice as high as for nonobese women. Although there have been concerns that being overweight or obese may decrease the efficacy of COCs, evidence suggests that COC efficacy is similar for normal-weight and overweight/obese women [<a href="#rid114">114</a>]. Practically, adherence to COCs likely plays a larger role in COC failure than the contribution of obesity. (See  <a class="medical medical_review" href="/z/d/html/5470.html" rel="external">"Contraception: Counseling for females with obesity", section on 'Risk of thromboembolism'</a> and  <a class="medical medical_review" href="/z/d/html/5470.html" rel="external">"Contraception: Counseling for females with obesity", section on 'Oral contraceptives'</a>.)</p><p class="headingAnchor" id="H489992166"><span class="h2">Postpartum and/or lactating</span><span class="headingEndMark"> — </span>We, and other experts, following the World Health Organization and the American College of Obstetricians and Gynecologists recommendations for nonhormonal and hormonal contraception in postpartum women, including those who are lactating [<a href="#rid16">16,17</a>]. COCs should not be used in the early postpartum weeks because of the high risk of thromboembolism [<a href="#rid15">15,16</a>]. This topic is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6708.html" rel="external">"Contraception: Postpartum counseling and methods", section on 'Short-acting hormonal contraception'</a>.)</p><p class="headingAnchor" id="H2657026737"><span class="h2">Perimenopause</span><span class="headingEndMark"> — </span>COCs containing 20 mcg of ethinyl estradiol are often used for nonsmoking perimenopausal women who desire contraception but who also have irregular or heavy menses and/or hormonally related symptoms that impair quality of life [<a href="#rid43">43</a>]. These preparations provide more than enough estrogen to relieve vasomotor flushes (which often begin during the perimenopausal transition). One problem that perimenopausal women often experience when taking COCs is recurrence of hot flashes and premenstrual mood disturbances during the seven-day pill-free interval. Some preparations contain 10 mcg of ethinyl estradiol on five of the seven "placebo" days, which may be helpful in relieving these symptoms. Continuous administration of the pill is another way to avoid the recurrence of hot flashes. COCs containing only 10 mcg of ethinyl estradiol are now also available and can be a good option for this population  (<a class="graphic graphic_table graphicRef82147" href="/z/d/graphic/82147.html" rel="external">table 4</a>). Because age is an independent risk factor for cardiovascular disease and thromboembolism, perimenopausal women with other medical conditions such as obesity, diabetes, and hypertension should avoid estrogen-containing contraception [<a href="#rid17">17</a>]. (See <a class="local">'Dosing regimens'</a> above and  <a class="medical medical_review" href="/z/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy", section on 'Use of oral contraceptives during the menopausal transition'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Cardiovascular effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis", section on 'Obesity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis", section on 'Age'</a>.)</p><p></p><p class="headingAnchor" id="H2580162532"><span class="h1">RESOURCES FOR PATIENTS AND CLINICIANS</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.bedsider.org%2F&amp;token=h7Ird6MEQJ0ciS3wlIS74wS%2BbqJQEspyaSo36FRNdkGJJnrJaPDlUEGuXmILPu5F&amp;TOPIC_ID=7398" target="_blank">bedsider.org</a> – A free website developed by the National Campaign to Prevent Teen and Unplanned Pregnancy, a private nonprofit group</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.choiceproject.wustl.edu%2F&amp;token=%2BnVJmPhZ7CoZ6P5TTscsQMEfRjhRSH%2BHYjLFHmNv8MpZBNOY80TFEfWmQJ4v5GVF&amp;TOPIC_ID=7398" target="_blank">CHOICE Project</a> – A free website sponsored by the Washington University School of Medicine in St. Louis that provides resources on contraceptive options and training resources for clinicians</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fyoungwomenshealth.org%2F&amp;token=9SOQ31M5muHbxxUii9uduj7uOdQP%2BNVKJGoE4M4lyiOJKXEoosD%2FJno5DMXZnUfG&amp;TOPIC_ID=7398" target="_blank">Center for Young Women's Health</a> – A free website run by Boston Children's Hospital that addresses reproductive health needs of teens and young adults</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fbeyondthepill.ucsf.edu%2F&amp;token=fttfTRGBi4dPw6uXwXDlebLq6gqwpTXS04i8%2BZvnWbO91%2Bn%2BSCxS3t417U%2FzXuYs&amp;TOPIC_ID=7398" target="_blank">Beyond the Pill</a> – A free website run by the University of California San Francisco</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.sexandu.ca%2F&amp;token=vdCs7dqmABYrTYLl86e3UBvZDVaCgDBYOgHXgKrHwtk%3D&amp;TOPIC_ID=7398" target="_blank">SexandU.ca</a> – An educational site run by the Society of Obstetricians and Gynaecologists of Canada that includes descriptions of various methods and a tool to help with selection of birth control</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.plannedparenthood.org%2F&amp;token=xXI%2By9QNEPjV52%2B%2BDeHAeZ9SXc2ukqt22nAmmnoIhbmjKCcbIKeiWKTXDj94bQ%2F4&amp;TOPIC_ID=7398" target="_blank">Planned Parenthood</a> – A nonprofit organization dedicated to reproductive health, with resources for patients and clinicians</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2Fwomens-health&amp;token=IQxLzDq4doJGUgaZgeIY00wsaOzEdxuM4iSYoaho0JryhrLyHr9romYrxnZ%2B9XAF&amp;TOPIC_ID=7398" target="_blank">ACOG Contraceptive FAQs</a> – American College of Obstetricians and Gynecologists (ACOG) addresses frequently asked questions (FAQs) about contraception</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2Fprograms%2Flong-acting-reversible-contraception-larc&amp;token=U83nmWJdEnYplmY9VjWreX3HVdeM4iV5pW6eK0VWJFBp3n3w1ajFQOAV2mS7Cgk1PHjvV%2B4Qkzpl360fr4RK8M6MULij1Bk7TNBpJyQfoTk%3D&amp;TOPIC_ID=7398" target="_blank">ACOG LARC Program</a> – ACOG Long-Acting Reversible Contraception (LARC) Program</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fvolumes%2F65%2Frr%2Frr6503a1.htm%3Fs_cid%3Drr6503a1_w&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLDUG08ZbGAJiu0qbyu%2F2zoIMVxNz7qTN91sychfwmBjXnjAf2YtkLNeW%2BABX%2FWfw04tcvgAO1wSmuCs3zXaWpQk%3D&amp;TOPIC_ID=7398" target="_blank">United States Medical Eligibility Criteria for Contraceptive Use</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fvolumes%2F65%2Frr%2Frr6504a1.htm%3Fs_cid%3Drr6504a1_w&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLDUG08ZbGAJiu0qbyu%2F2zoI9S6tDFFGkqrofEu6x4BLSnjAf2YtkLNeW%2BABX%2FWfw0wprhImEEGXBTJh4uBFC8ZY%3D&amp;TOPIC_ID=7398" target="_blank">United States Selected Practice Recommendations for Contraceptive Use</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fsrh.org%2Fstandards-and-guidance%2Fuk-medical-eligibility-criteria-for-contraceptive-use-ukmec%2F&amp;token=ztieazJ5uRGS8OAK6OtndEYnq3uKPVq18X9Ddxm72xPEH4nsXWa8ALPDG2co625wReNVUbS4q%2FomInVfqXXKsFP4k2y2iFHZK825biHdFJOGYrcKNH3K1cyAcdXFm3QP&amp;TOPIC_ID=7398" target="_blank">UK Medical Eligibility Criteria for Contraceptive Use</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2F9789241549158&amp;token=mr3MkQMxxRm373pPGLTYB%2B8L7rJeOJtqYOfpSLq18h7bLDDnWC3XicBcpsIGU3t1%2BeMBqFM7dNdQ9NPFnY3uWg%3D%3D&amp;TOPIC_ID=7398" target="_blank">World Health Organization (WHO) Medical Eligibility Criteria for Contraceptive Use</a></p><p></p><p class="headingAnchor" id="H1369797971"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112268.html" rel="external">"Society guideline links: Contraception"</a>.)</p><p class="headingAnchor" id="H1286158566"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16162.html" rel="external">"Patient education: Hormonal birth control (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/15349.html" rel="external">"Patient education: Choosing birth control (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/8423.html" rel="external">"Patient education: Long-acting methods of birth control (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/8419.html" rel="external">"Patient education: Hormonal methods of birth control (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/8421.html" rel="external">"Patient education: Birth control; which method is right for me? (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3681523291"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Our approach</strong> – In general, we prefer generic, monophasic, low dose (≤35 mcg of ethinyl estradiol), and 24/4 cycle pills. Pills containing 50 mcg of estrogen should not be used for contraception. (See <a class="local">'Our approach to COC selection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monophasic versus other regimens</strong> – Monophasic pills contain the same dose of estrogen and progestin in each of the hormonally active pills. Biphasic or triphasic pills have varying doses of hormones across the cycle (usually the progestin). There are no proven advantages to the multiphasic regimens (ie, less unscheduled bleeding or efficacy). (See <a class="local">'Dosing regimens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hormone types and dose</strong> – Most COCs on average contain 20 to 35 mcg of ethinyl estradiol. Newer formulations include estradiol valerate, estetrol, and 17-beta estradiol  (<a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">table 1</a>). Most available progestins have varying degrees of progestogenic and androgenic activity  (<a class="graphic graphic_table graphicRef120135" href="/z/d/graphic/120135.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef78782" href="/z/d/graphic/78782.html" rel="external">table 6</a>). However, when combined with estrogen, the overall effect of COCs is antiandrogenic. (See <a class="local">'Hormone components'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action and efficacy</strong> – While combined estrogen-progestin oral contraceptives (COCs) have several mechanisms of contraceptive action, the most important is inhibition of folliculogenesis and the midcycle luteinizing hormone surge so that ovulation does not occur. (See <a class="local">'Mechanisms of action'</a> above.)</p><p></p><p class="bulletIndent1">When taken properly, COCs are a highly effective form of contraception with a typical-use failure rate of approximately 7 percent for products containing ethinyl estradiol  (<a class="graphic graphic_figure graphicRef119765" href="/z/d/graphic/119765.html" rel="external">figure 1</a> and <a class="graphic graphic_table graphicRef69223" href="/z/d/graphic/69223.html" rel="external">table 1</a>). Unintended pregnancies commonly result from missed pills or failure to resume therapy after the seven-day pill-free interval. (See <a class="local">'Efficacy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Starting combined oral contraceptives</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial evaluation</strong> – Hormonal contraception can be safely provided after a medical history and blood pressure measurement; a pelvic examination is not required. Additional testing is not warranted in medically uncomplicated individuals. (See <a class="local">'Initiation'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Assess</strong> <strong>medical comorbidities</strong> – Both the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) provide comprehensive tables of medical conditions and personal characteristics that may affect contraceptive choice. (See <a class="local">'Candidates'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F181468%2F9789241549158_eng.pdf&amp;token=n6AKfPMLO9no%2BCQ6AfHDii7sbay3dEwW4U5WgmUeAmSyIYzji9%2BF1lOqBBPOTPPcT4tVCzsD4vn9jlct6ayBxQSmDqBTeNp0ZZSS3AqYiKg%3D&amp;TOPIC_ID=7398" target="_blank">WHO Medical Eligibility Criteria for Contraceptive Use 2015</a> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=7398" target="_blank">CDC's Summary Chart of US Medical Eligibility Criteria</a> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>When to start</strong> – COCs can be started at any time during the cycle. The preferred approach is the quick start method in which the individual begins taking COCs on the day that the prescription is given (once pregnancy has been reasonably excluded) regardless of menstrual cycle timing  (<a class="graphic graphic_algorithm graphicRef56863" href="/z/d/graphic/56863.html" rel="external">algorithm 1</a>). Backup contraception is used for an additional seven days  (<a class="graphic graphic_table graphicRef89825" href="/z/d/graphic/89825.html" rel="external">table 7</a>). (See <a class="local">'Administration and use'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Missed pills</strong> – We suggest that backup contraception be used for seven days after two missed pills, regardless of pill dose (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Missed pills'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs that impact COC metabolism</strong> – The metabolism of COCs is accelerated by any drug that increases liver microsomal enzyme activity, such as many of the antiseizure medications, including <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> and <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>. The metabolism of COCs is <strong>not </strong>affected by antibiotics, with the exception of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>. (See <a class="local">'Drug interactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Continuous or extended-use contraceptives</strong> – Contraceptive efficacy, safety, and patient satisfaction are similar for cyclic, extended, and continuous regimens. Menses-related symptoms are typically reduced with combinations that reduce the frequency of withdrawal bleeding. However, individuals using extended or continuous COCs may have more unpredictable bleeding or spotting events in the first three to six months of use compared with cyclic use; this unscheduled bleeding will decrease over time. (See <a class="local">'Continuous or extended use'</a> above.)</p><p></p><p class="headingAnchor" id="H1132142129"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Kathryn Martin, MD, and Robert Barbieri, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sech LA, Mishell DR Jr. Oral steroid contraception. Womens Health (Lond) 2015; 11:743.</a></li><li><a class="nounderline abstract_t">Hannaford PC, Iversen L, Macfarlane TV, et al. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ 2010; 340:c927.</a></li><li><a class="nounderline abstract_t">Madden T, Secura GM, Nease RF, et al. The role of contraceptive attributes in women's contraceptive decision making. Am J Obstet Gynecol 2015; 213:46.e1.</a></li><li class="breakAll">Speroff &amp; Darney's Clinical Guide to Contraception, 6th, Jensen JT, Creinin MD (Eds), Wolters Kluwer, Philadelphia 2020.</li><li><a class="nounderline abstract_t">Gallo MF, Nanda K, Grimes DA, et al. 20 µg versus &gt;20 µg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev 2013; :CD003989.</a></li><li><a class="nounderline abstract_t">de Bastos M, Stegeman BH, Rosendaal FR, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014; :CD010813.</a></li><li><a class="nounderline abstract_t">Lidegaard Ø, Løkkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366:2257.</a></li><li><a class="nounderline abstract_t">Weill A, Dalichampt M, Raguideau F, et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ 2016; 353:i2002.</a></li><li><a class="nounderline abstract_t">Edelman AB, Gallo MF, Jensen JT, et al. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005; :CD004695.</a></li><li><a class="nounderline abstract_t">Han L, Jensen JT. Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk? Obstet Gynecol Clin North Am 2015; 42:683.</a></li><li class="breakAll">Faculty of Sexual &amp; Reproductive Healthcare. Clinical Guidance: Combined Hormonal Contraception. www.ceuguidancecombinedhormonalcontraception.pdf. (Accessed on June 07, 2018).</li><li><a class="nounderline abstract_t">London A, Jensen JT. Rationale for eliminating the hormone-free interval in modern oral contraceptives. Int J Gynaecol Obstet 2016; 134:8.</a></li><li><a class="nounderline abstract_t">Crosignani PG, Testa G, Vegetti W, Parazzini F. Ovarian activity during regular oral contraceptive use. Contraception 1996; 54:271.</a></li><li><a class="nounderline abstract_t">Baerwald AR, Olatunbosun OA, Pierson RA. Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. Contraception 2004; 70:371.</a></li><li><a class="nounderline abstract_t">Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.</a></li><li class="breakAll">Department of Reproductive Health, World Health Organization. Medical eligibility criteria for contraceptive use, 5th ed, World Health Organization, Geneva 2015.</li><li><a class="nounderline abstract_t">ACOG Practice Bulletin No. 206: Use of Hormonal Contraception in Women With Coexisting Medical Conditions. Obstet Gynecol 2019; 133:e128. Reaffirmed 2022.</a></li><li class="breakAll">Trussell J, Aiken ARA, Micks E, Guthrie K. Efficacy, safety, and personal considerations. In: Contraceptive Technology, 21st ed, Hatcher RA, Nelson AL, Trussell J, et al (Eds), Ayer Company Publishers, Inc., New York 2018.</li><li><a class="nounderline abstract_t">Sober SP, Schreiber CA. Controversies in family planning: are all oral contraceptive formulations created equal? Contraception 2011; 83:394.</a></li><li><a class="nounderline abstract_t">Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998; 179:577.</a></li><li><a class="nounderline abstract_t">Generic OCs bioequivalent, but much maligned. Contracept Technol Update 1989; 10:77.</a></li><li><a class="nounderline abstract_t">Archer DF, Nakajima ST, Sawyer AT, et al. Norethindrone acetate 1.0 milligram and ethinyl estradiol 10 micrograms as an ultra low-dose oral contraceptive. Obstet Gynecol 2013; 122:601.</a></li><li><a class="nounderline abstract_t">Creinin MD, Westhoff CL, Bouchard C, et al. Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results. Contraception 2021; 104:222.</a></li><li><a class="nounderline abstract_t">Creinin MD, Jensen JT, Chen MJ, et al. Combined Oral Contraceptive Adherence and Pregnancy Rates. Obstet Gynecol 2023; 141:989.</a></li><li><a class="nounderline abstract_t">Jensen JT. Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest. Expert Opin Pharmacother 2010; 11:1147.</a></li><li class="breakAll">Nextstellis (drospirenone and estetrol tablets). US FDA approved product information; Greenville, NC: Mayne Pharma LLC; April 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214154s000lbl.pdf (Accessed on April 16, 2021).</li><li><a class="nounderline abstract_t">Van Vliet HA, Grimes DA, Lopez LM, et al. Triphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev 2011; 2011:CD003553.</a></li><li><a class="nounderline abstract_t">Van Vliet HA, Raps M, Lopez LM, Helmerhorst FM. Quadriphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev 2011; :CD009038.</a></li><li><a class="nounderline abstract_t">Van Vliet HA, Grimes DA, Helmerhorst FM, Schulz KF. Biphasic versus triphasic oral contraceptives for contraception. Cochrane Database Syst Rev 2006; :CD003283.</a></li><li><a class="nounderline abstract_t">Lawrie TA, Helmerhorst FM, Maitra NK, et al. Types of progestogens in combined oral contraception: effectiveness and side-effects. Cochrane Database Syst Rev 2011; :CD004861.</a></li><li><a class="nounderline abstract_t">Van Vliet H, Grimes D, Helmerhorst F, Schulz K. Biphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev 2001; :CD002032.</a></li><li><a class="nounderline abstract_t">Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe). Contraception 2007; 75:16.</a></li><li><a class="nounderline abstract_t">Vandever MA, Kuehl TJ, Sulak PJ, et al. Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens. Contraception 2008; 77:162.</a></li><li><a class="nounderline abstract_t">Fels H, Steward R, Melamed A, et al. Comparison of serum and cervical mucus hormone levels during hormone-free interval of 24/4 vs. 21/7 combined oral contraceptives. Contraception 2013; 87:732.</a></li><li><a class="nounderline abstract_t">Sullivan H, Furniss H, Spona J, Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril 1999; 72:115.</a></li><li><a class="nounderline abstract_t">Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 2011; 117:33.</a></li><li><a class="nounderline abstract_t">ACOG Practice Bulletin No. 110: noncontraceptive uses of hormonal contraceptives. Obstet Gynecol 2010; 115:206. Reaffirmed 2020.</a></li><li><a class="nounderline abstract_t">Grimes DA, Jones LB, Lopez LM, Schulz KF. Oral contraceptives for functional ovarian cysts. Cochrane Database Syst Rev 2009; :CD006134.</a></li><li><a class="nounderline abstract_t">Carr BR, Parker CR Jr, Madden JD, et al. Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment. J Clin Endocrinol Metab 1979; 49:346.</a></li><li><a class="nounderline abstract_t">Iversen L, Sivasubramaniam S, Lee AJ, et al. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study. Am J Obstet Gynecol 2017; 216:580.e1.</a></li><li><a class="nounderline abstract_t">Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol 2013; 31:4188.</a></li><li><a class="nounderline abstract_t">Gambacciani M, Cappagli B, Lazzarini V, et al. Longitudinal evaluation of perimenopausal bone loss: effects of different low dose oral contraceptive preparations on bone mineral density. Maturitas 2006; 54:176.</a></li><li><a class="nounderline abstract_t">Allen RH, Cwiak CA, Kaunitz AM. Contraception in women over 40 years of age. CMAJ 2013; 185:565.</a></li><li><a class="nounderline abstract_t">Shapiro S, Dinger J. Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies. J Fam Plann Reprod Health Care 2010; 36:33.</a></li><li><a class="nounderline abstract_t">Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361:1159.</a></li><li><a class="nounderline abstract_t">Mohllajee AP, Curtis KM, Martins SL, Peterson HB. Hormonal contraceptive use and risk of sexually transmitted infections: a systematic review. Contraception 2006; 73:154.</a></li><li><a class="nounderline abstract_t">Morrison CS, Turner AN, Jones LB. Highly effective contraception and acquisition of HIV and other sexually transmitted infections. Best Pract Res Clin Obstet Gynaecol 2009; 23:263.</a></li><li><a class="nounderline abstract_t">Rubin GL, Ory HW, Layde PM. Oral contraceptives and pelvic inflammatory disease. Am J Obstet Gynecol 1982; 144:630.</a></li><li><a class="nounderline abstract_t">Rezk M, Sayyed T, Masood A, Dawood R. Risk of bacterial vaginosis, Trichomonas vaginalis and Candida albicans infection among new users of combined hormonal contraception vs LNG-IUS. Eur J Contracept Reprod Health Care 2017; 22:344.</a></li><li><a class="nounderline abstract_t">Bradshaw CS, Walker J, Fairley CK, et al. Prevalent and incident bacterial vaginosis are associated with sexual and contraceptive behaviours in young Australian women. PLoS One 2013; 8:e57688.</a></li><li><a class="nounderline abstract_t">Vodstrcil LA, Hocking JS, Law M, et al. Hormonal contraception is associated with a reduced risk of bacterial vaginosis: a systematic review and meta-analysis. PLoS One 2013; 8:e73055.</a></li><li><a class="nounderline abstract_t">Polis CB, Phillips SJ, Curtis KM, et al. Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence. Contraception 2014; 90:360.</a></li><li><a class="nounderline abstract_t">Polis CB, Phillips SJ, Curtis KM. Hormonal contraceptive use and female-to-male HIV transmission:  a systematic review of the epidemiologic evidence. AIDS 2013; 27:493.</a></li><li><a class="nounderline abstract_t">Phillips SJ, Polis CB, Curtis KM. The safety of hormonal contraceptives for women living with HIV and their sexual partners. Contraception 2016; 93:11.</a></li><li><a class="nounderline abstract_t">Phillips SJ, Curtis KM, Polis CB. Effect of hormonal contraceptive methods on HIV disease progression: a systematic review. AIDS 2013; 27:787.</a></li><li><a class="nounderline abstract_t">Tepper NK, Curtis KM, Cox S, Whiteman MK. Update to U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Updated Recommendations for the Use of Contraception Among Women at High Risk for HIV Infection. MMWR Morb Mortal Wkly Rep 2020; 69:405.</a></li><li><a class="nounderline abstract_t">Stanczyk FZ, Archer DF, Bhavnani BR. Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. Contraception 2013; 87:706.</a></li><li><a class="nounderline abstract_t">Christin-Maitre S, Laroche E, Bricaire L. A new contraceptive pill containing 17β-estradiol and nomegestrol acetate. Womens Health (Lond) 2013; 9:13.</a></li><li><a class="nounderline abstract_t">Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982; 144:511.</a></li><li><a class="nounderline abstract_t">Kangasniemi MH, Arffman RK, Haverinen A, et al. Effects of estradiol- and ethinylestradiol-based contraceptives on adrenal steroids: A randomized trial. Contraception 2022; 116:59.</a></li><li><a class="nounderline abstract_t">Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception 2016; 94:328.</a></li><li><a class="nounderline abstract_t">Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. Br Med J 1968; 2:199.</a></li><li><a class="nounderline abstract_t">Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev 2013; 34:171.</a></li><li><a class="nounderline abstract_t">Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006; 12:169.</a></li><li><a class="nounderline abstract_t">Sitruk-Ware R, Nath A. The use of newer progestins for contraception. Contraception 2010; 82:410.</a></li><li><a class="nounderline abstract_t">Foidart JM, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000; 5:124.</a></li><li><a class="nounderline abstract_t">Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005; 106:492.</a></li><li><a class="nounderline abstract_t">Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72:414.</a></li><li><a class="nounderline abstract_t">Martin KA, Anderson RR, Chang RJ, et al. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018; 103:1233.</a></li><li><a class="nounderline abstract_t">Loughlin J, Seeger JD, Eng PM, et al. Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives. Contraception 2008; 78:377.</a></li><li><a class="nounderline abstract_t">Schütt B, Kunz M, Blode H. Coadministration of estradiol/drospirenone and indomethacin does not cause hyperkalemia in healthy postmenopausal women: a randomized open-label crossover study. J Clin Pharmacol 2007; 47:774.</a></li><li><a class="nounderline abstract_t">Bird ST, Pepe SR, Etminan M, et al. The association between drospirenone and hyperkalemia: a comparative-safety study. BMC Clin Pharmacol 2011; 11:23.</a></li><li><a class="nounderline abstract_t">Mona Eng P, Seeger JD, Loughlin J, et al. Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes. Contraception 2007; 75:101.</a></li><li class="breakAll">Daily Med. National Institutes of Health. U.S. National Library of Medicine. U.S. Department of Health and Human Services. www.dailymed.nlm.nih.gov/dailymed/ (Accessed on May 17, 2019).</li><li><a class="nounderline abstract_t">Stanczyk FZ. All progestins are not created equal. Steroids 2003; 68:879.</a></li><li><a class="nounderline abstract_t">Zimmerman Y, Eijkemans MJ, Coelingh Bennink HJ, et al. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update 2014; 20:76.</a></li><li><a class="nounderline abstract_t">Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012; :CD004425.</a></li><li><a class="nounderline abstract_t">Barrionuevo P, Nabhan M, Altayar O, et al. Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis. J Clin Endocrinol Metab 2018; 103:1258.</a></li><li><a class="nounderline abstract_t">Dragoman M, Curtis KM, Gaffield ME. Combined hormonal contraceptive use among women with known dyslipidemias: a systematic review of critical safety outcomes. Contraception 2016; 94:280.</a></li><li><a class="nounderline abstract_t">Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Greater inhibition of the pituitary--ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 2006; 74:100.</a></li><li><a class="nounderline abstract_t">Archer DF, Jensen JT, Johnson JV, et al. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 2006; 74:439.</a></li><li><a class="nounderline abstract_t">Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 2003; 101:653.</a></li><li><a class="nounderline abstract_t">Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003; 68:89.</a></li><li><a class="nounderline abstract_t">Legro RS, Pauli JG, Kunselman AR, et al. Effects of continuous versus cyclical oral contraception: a randomized controlled trial. J Clin Endocrinol Metab 2008; 93:420.</a></li><li><a class="nounderline abstract_t">Johnson JV, Grubb GS, Constantine GD. Endometrial histology following 1 year of a continuous daily regimen of levonorgestrel 90 micro g/ethinyl estradiol 20 micro g. Contraception 2007; 75:23.</a></li><li><a class="nounderline abstract_t">Sulak PJ, Smith V, Coffee A, et al. Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial. Obstet Gynecol 2008; 112:563.</a></li><li><a class="nounderline abstract_t">Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.</a></li><li><a class="nounderline abstract_t">Grindlay K, Burns B, Grossman D. Prescription requirements and over-the-counter access to oral contraceptives: a global review. Contraception 2013; 88:91.</a></li><li><a class="nounderline abstract_t">Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ 1996; 313:1127.</a></li><li><a class="nounderline abstract_t">Westhoff C, Heartwell S, Edwards S, et al. Initiation of oral contraceptives using a quick start compared with a conventional start: a randomized controlled trial. Obstet Gynecol 2007; 109:1270.</a></li><li><a class="nounderline abstract_t">Lopez LM, Newmann SJ, Grimes DA, et al. Immediate start of hormonal contraceptives for contraception. Cochrane Database Syst Rev 2012; 12:CD006260.</a></li><li><a class="nounderline abstract_t">Whalen KL, Rose R. Estradiol valerate/dienogest: a novel oral contraceptive. Ann Pharmacother 2011; 45:1256.</a></li><li><a class="nounderline abstract_t">Schwartz JL, Creinin MD, Pymar HC, Reid L. Predicting risk of ovulation in new start oral contraceptive users. Obstet Gynecol 2002; 99:177.</a></li><li class="breakAll">UK Medical Eligibility Criteria for Contraceptive Use, 2016. The Faculty of Sexual and Reproductive Healthcare of the Royal College of Obstetricians and Gynaecologists. May 2016. www.fsrh.org/ukmec/ (Accessed on May 17, 2019).</li><li><a class="nounderline abstract_t">Foster DG, Parvataneni R, de Bocanegra HT, et al. Number of oral contraceptive pill packages dispensed, method continuation, and costs. Obstet Gynecol 2006; 108:1107.</a></li><li><a class="nounderline abstract_t">Judge-Golden CP, Smith KJ, Mor MK, Borrero S. Financial Implications of 12-Month Dispensing of Oral Contraceptive Pills in the veterans Affiars Health Care System. JAMA Intern Med 2019.</a></li><li><a class="nounderline abstract_t">Mansour D, Fraser IS. Missed contraceptive pills and the critical pill-free interval. Lancet 2005; 365:1670.</a></li><li><a class="nounderline abstract_t">Birtch RL, Olatunbosun OA, Pierson RA. Ovarian follicular dynamics during conventional vs. continuous oral contraceptive use. Contraception 2006; 73:235.</a></li><li><a class="nounderline abstract_t">Zapata LB, Steenland MW, Brahmi D, et al. Effect of missed combined hormonal contraceptives on contraceptive effectiveness: a systematic review. Contraception 2013; 87:685.</a></li><li><a class="nounderline abstract_t">Santoro N, Crawford SL, El Khoudary SR, et al. Menstrual Cycle Hormone Changes in Women Traversing Menopause: Study of Women's Health Across the Nation. J Clin Endocrinol Metab 2017; 102:2218.</a></li><li><a class="nounderline abstract_t">Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev 2009; 30:465.</a></li><li><a class="nounderline abstract_t">Shifren JL, Gass ML, NAMS Recommendations for Clinical Care of Midlife Women Working Group. The North American Menopause Society recommendations for clinical care of midlife women. Menopause 2014; 21:1038.</a></li><li><a class="nounderline abstract_t">te Velde ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update 2002; 8:141.</a></li><li><a class="nounderline abstract_t">Crawford P, Chadwick DJ, Martin C, et al. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 1990; 30:892.</a></li><li><a class="nounderline abstract_t">Zhanel GG, Siemens S, Slayter K, Mandell L. Antibiotic and oral contraceptive drug interactions: Is there a need for concern? Can J Infect Dis 1999; 10:429.</a></li><li><a class="nounderline abstract_t">Simmons KB, Haddad LB, Nanda K, Curtis KM. Drug interactions between rifamycin antibiotics and hormonal contraception: a systematic review. BJOG 2018; 125:804.</a></li><li><a class="nounderline abstract_t">Wilbur K, Ensom MH. Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants. Clin Pharmacokinet 2000; 38:355.</a></li><li><a class="nounderline abstract_t">Wegner I, Edelbroek PM, Bulk S, Lindhout D. Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives. Neurology 2009; 73:1388.</a></li><li><a class="nounderline abstract_t">Christensen J, Petrenaite V, Atterman J, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia 2007; 48:484.</a></li><li><a class="nounderline abstract_t">Sabers A, Ohman I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003; 61:570.</a></li><li><a class="nounderline abstract_t">Simmons KB, Haddad LB, Nanda K, Curtis KM. Drug interactions between non-rifamycin antibiotics and hormonal contraception: a systematic review. Am J Obstet Gynecol 2018; 218:88.</a></li><li><a class="nounderline abstract_t">Aronson JK, Ferner RE. Analysis of reports of unintended pregnancies associated with the combined use of non-enzyme-inducing antibiotics and hormonal contraceptives. BMJ Evid Based Med 2021; 26:112.</a></li><li><a class="nounderline abstract_t">Berry-Bibee EN, Kim MJ, Tepper NK, et al. Co-administration of St. John's wort and hormonal contraceptives: a systematic review. Contraception 2016; 94:668.</a></li><li><a class="nounderline abstract_t">Lopez LM, Bernholc A, Chen M, et al. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev 2016; :CD008452.</a></li></ol></div><div id="topicVersionRevision">Topic 7398 Version 72.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26673988" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Oral steroid contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20223876" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25644443" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The role of contraceptive attributes in women's contraceptive decision making.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25644443" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The role of contraceptive attributes in women's contraceptive decision making.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23904209" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 20µg versus&gt;20µg estrogen combined oral contraceptives for contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24590565" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Combined oral contraceptives: venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22693997" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Thrombotic stroke and myocardial infarction with hormonal contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27164970" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16034942" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26598309" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26598309" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27067074" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Rationale for eliminating the hormone-free interval in modern oral contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8934059" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Ovarian activity during regular oral contraceptive use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15504375" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30681544" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : ACOG Practice Bulletin No. 206: Use of Hormonal Contraception in Women With Coexisting Medical Conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30681544" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : ACOG Practice Bulletin No. 206: Use of Hormonal Contraception in Women With Coexisting Medical Conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21477679" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Controversies in family planning: are all oral contraceptive formulations created equal?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9757954" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12342313" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Generic OCs bioequivalent, but much maligned.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23921878" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Norethindrone acetate 1.0 milligram and ethinyl estradiol 10 micrograms as an ultra low-dose oral contraceptive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34000251" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37023457" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Combined Oral Contraceptive Adherence and Pregnancy Rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20367275" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20367275" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22071807" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Triphasic versus monophasic oral contraceptives for contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22071862" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Quadriphasic versus monophasic oral contraceptives for contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16856002" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Biphasic versus triphasic oral contraceptives for contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21563141" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Types of progestogens in combined oral contraception: effectiveness and side-effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11687135" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Biphasic versus monophasic oral contraceptives for contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17161118" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18279685" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23352800" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Comparison of serum and cervical mucus hormone levels during hormone-free interval of 24/4 vs. 21/7 combined oral contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10428158" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21213475" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20027071" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : ACOG Practice Bulletin No. 110: noncontraceptive uses of hormonal contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19370628" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Oral contraceptives for functional ovarian cysts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/224073" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28188769" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24145348" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16332417" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Longitudinal evaluation of perimenopausal bone loss: effects of different low dose oral contraceptive preparations on bone mineral density.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23460635" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Contraception in women over 40 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20067670" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12686037" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cervical cancer and use of hormonal contraceptives: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16413846" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hormonal contraceptive use and risk of sexually transmitted infections: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19211309" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Highly effective contraception and acquisition of HIV and other sexually transmitted infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7137247" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Oral contraceptives and pelvic inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28849960" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Risk of bacterial vaginosis, Trichomonas vaginalis and Candida albicans infection among new users of combined hormonal contraception vs LNG-IUS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23472099" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prevalent and incident bacterial vaginosis are associated with sexual and contraceptive behaviours in young Australian women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24023807" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Hormonal contraception is associated with a reduced risk of bacterial vaginosis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25183264" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23079808" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Hormonal contraceptive use and female-to-male HIV transmission:  a systematic review of the epidemiologic evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26515194" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The safety of hormonal contraceptives for women living with HIV and their sexual partners.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23135169" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Effect of hormonal contraceptive methods on HIV disease progression: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32271729" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Update to U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Updated Recommendations for the Use of Contraception Among Women at High Risk for HIV Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23375353" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23241152" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A new contraceptive pill containing 17β-estradiol and nomegestrol acetate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6291391" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Comparison of pharmacodynamic properties of various estrogen formulations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36084710" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effects of estradiol- and ethinylestradiol-based contraceptives on adrenal steroids: A randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27343748" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Impact of estrogen type on cardiovascular safety of combined oral contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5653025" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Investigation of relation between use of oral contraceptives and thromboembolic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23238854" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16291771" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : New progestagens for contraceptive use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20933114" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The use of newer progestins for contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10943575" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135578" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16307962" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29522147" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18929734" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17463217" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Coadministration of estradiol/drospirenone and indomethacin does not cause hyperkalemia in healthy postmenopausal women: a randomized open-label crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22208934" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The association between drospirenone and hyperkalemia: a comparative-safety study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17241838" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17241838" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14667980" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : All progestins are not created equal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24082040" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22786490" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Combined oral contraceptive pills for treatment of acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29522176" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26272309" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Combined hormonal contraceptive use among women with known dyslipidemias: a systematic review of critical safety outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16860046" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Greater inhibition of the pituitary--ovarian axis in oral contraceptive regimens with a shortened hormone-free interval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17157099" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12681866" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12954519" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A multicenter, randomized study of an extended cycle oral contraceptive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18056769" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Effects of continuous versus cyclical oral contraception: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17161119" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Endometrial histology following 1 year of a continuous daily regimen of levonorgestrel 90 micro g/ethinyl estradiol 20 micro g.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18757653" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467319" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : U.S. Selected Practice Recommendations for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23352799" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Prescription requirements and over-the-counter access to oral contraceptives: a global review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8916702" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Factor V Leiden: should we screen oral contraceptive users and pregnant women?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17540797" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Initiation of oral contraceptives using a quick start compared with a conventional start: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23235628" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Immediate start of hormonal contraceptives for contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21917554" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Estradiol valerate/dienogest: a novel oral contraceptive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11814492" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Predicting risk of ovulation in new start oral contraceptive users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11814492" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Predicting risk of ovulation in new start oral contraceptive users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17077231" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Number of oral contraceptive pill packages dispensed, method continuation, and costs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Financial Implications of 12-Month Dispensing of Oral Contraceptive Pills in the veterans Affiars Health Care System</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15894085" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Missed contraceptive pills and the critical pill-free interval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16472562" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Ovarian follicular dynamics during conventional vs. continuous oral contraceptive use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23083527" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Effect of missed combined hormonal contraceptives on contraceptive effectiveness: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28368525" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Menstrual Cycle Hormone Changes in Women Traversing Menopause: Study of Women's Health Across the Nation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19589949" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Ovarian aging: mechanisms and clinical consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25225714" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The North American Menopause Society recommendations for clinical care of midlife women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12099629" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : The variability of female reproductive ageing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2126946" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22346401" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Antibiotic and oral contraceptive drug interactions: Is there a need for concern?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29130574" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Drug interactions between rifamycin antibiotics and hormonal contraception: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10803456" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19858461" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17346247" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12939444" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Oral contraceptives reduce lamotrigine plasma levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28694152" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Drug interactions between non-rifamycin antibiotics and hormonal contraception: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32817012" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Analysis of reports of unintended pregnancies associated with the combined use of non-enzyme-inducing antibiotics and hormonal contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27444983" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Co-administration of St. John's wort and hormonal contraceptives: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27537097" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Hormonal contraceptives for contraception in overweight or obese women.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
